NCT04599647No Longer Available不适用
Expanded Access Protocol for the Treatment of Glioblastoma With PVSRIPO
适应症
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 试验地点
- 1
研究概览
简要总结
This is an open-label, single-arm, non-randomized, intermediate-sized expanded access study evaluating the safety, efficacy, and tolerability of PVSRIPO delivered via intratumoral infusion, in subjects with glioblastoma (GBM) who are ineligible to participate in clinical study with PVSRIPO that is currently open to enrollment.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
Available
不适用
Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221GBMGlioblastoma MultiformeNCT02146066Northwest Biotherapeutics
已完成
2 期
Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With GlioblastomaGlioblastomaNCT02799238CytoVac A/S62
Approved For Marketing
不适用
Axicabtagene Ciloleucel Expanded Access StudyRelapsed/Refractory Diffuse Large B Cell LymphomaRelapsed/Refractory Primary Mediastinal B Cell LymphomaRelapsed/Refractory Transformed Follicular LymphomaRelapsed/Refractory High-Grade B-Cell LymphomaNCT03153462Kite, A Gilead Company
进行中（未招募）
1 期
Safety and efficacy study of INC424 in patients with myelofibrosisEUCTR2010-024473-39-PLovartis Pharma Services AG2,500
进行中（未招募）
1 期
Safety and efficacy study of INC424 in patients with myelofibrosisEUCTR2010-024473-39-HUovartis Pharma Services AG2,500